

## A guide to cost-effectiveness acceptability curves

ELISABETH FENWICK and SARAH BYFORD

**Summary** Use of cost-effectiveness acceptability curves, as a method for summarising information on uncertainty in cost-effectiveness, has become widespread within applied studies. This includes several studies in the mental health field. This editorial uses examples from recent papers to illustrate how cost-effectiveness acceptability curves are constructed, what they represent and how they should be interpreted.

**Declaration of interest** None.

Mounting pressure on healthcare budgets has led to an increased emphasis on economic evidence to guide healthcare policy and practice decisions. This has meant an increase in demand for information concerning the costs and effectiveness of health technologies in order to determine their cost-effectiveness. The aim of cost-effectiveness analysis is to identify efficient use of scarce healthcare resources, through identifying the treatments and technologies that provide the maximum additional effects per additional unit of resource consumed. The same principles apply to the treatments, programmes and technologies that comprise mental health services, and there is a growing literature concerning the cost-effectiveness of these various services.

The cost-effectiveness acceptability curve (CEAC) is a relatively new concept that is featuring more frequently in cost-effectiveness papers within the medical literature. These curves illustrate the uncertainty surrounding the estimate of cost-effectiveness and were developed as a result of considerable debate regarding the best way to deal with such uncertainty (Van Hout *et al*, 1994; Briggs & Fenn, 1998; Briggs & Gray, 1999; O'Brien & Briggs, 2002). Since their conception, use of CEACs has become widespread within

applied studies, including a number in the mental health field (Bower *et al*, 2003; Byford *et al*, 2003; Haddock *et al*, 2003; Miller *et al*, 2003; Scott *et al*, 2003; McCrone *et al*, 2004). It has thus become important to understand what CEACs look like, how they are constructed, what they represent and how they should be interpreted. We discuss these issues with reference to recent papers (from this journal) that have included CEACs (Haddock *et al*, 2003; Scott *et al*, 2003; McCrone *et al*, 2004). We focus on CEACs derived from comparisons of two interventions. For evaluations comparing more than two interventions, see Fenwick *et al* (2001).


### WHAT DOES A CEAC LOOK LIKE?

A CEAC shows the probability that an intervention is cost-effective compared with the alternative, given the observed data, for a range of maximum monetary values ( $\lambda$ ) that a decision-maker might be willing to

pay for a particular unit change in outcome. A typical example of a CEAC is illustrated in Scott *et al* (2003: Fig. 1). Their figure shows the probability that cognitive therapy is cost-effective compared with standard clinical management with antidepressants, for a range of monetary values that a decision-maker might consider the maximum acceptable to avoid a depressive relapse. This range of maximum monetary values, expressed as £ per depressive relapse avoided, is given on the *x*-axis. Given a specified value of this 'acceptable' cost-effectiveness ratio (a point on the *x*-axis), the CEAC shows the probability that the data are consistent with a true cost-effectiveness ratio falling below that value (read off the *y*-axis).

### HOW IS A CEAC CONSTRUCTED?

Cost-effectiveness acceptability curves were introduced as an alternative to producing confidence intervals around incremental cost-effectiveness ratios (ICERs), which can be statistically challenging (Van Hout *et al*, 1994; Briggs & Fenn, 1998). The CEAC is derived from the joint distribution of incremental costs and incremental effects. The most common technique for estimating these joint distributions is non-parametric bootstrapping of the observed data, although other methods are available (Van Hout *et al*, 1994; Lothgren & Zethraeus, 2000; O'Brien & Briggs,



**Fig. 1** Scatter plot showing the mean differences in costs and in the primary outcome measure (Global Assessment of Functioning) from the trial data using 1000 bootstrap replicates (differences based on cognitive-behavioural therapy minus control). (Taken from Haddock *et al*, 2003.)

2002). A scatter plot of the bootstrapped incremental costs and effect pairs can be presented on the incremental cost-effectiveness plane, as shown in Fig. 1 (taken from Haddock *et al*, 2003). This illustrates the uncertainty surrounding the estimates of expected costs (here in £) and expected effects (Global Assessment of Functioning (GAF) scores) associated with the intervention (cognitive-behavioural therapy and motivational intervention) compared with the alternative (routine treatment).

The incremental cost-effectiveness plane is divided into four quadrants by the origin, with each quadrant having a different implication for economic evaluation. The SE quadrant, with negative costs and positive effects, represents the position where the intervention is more effective and less costly than the alternative ('dominates'). Interventions falling in this quadrant are always considered cost-effective regardless of the maximum acceptable ratio ( $\lambda$ ). The NW quadrant, with positive costs and negative effects, represents the position where the intervention is both more costly and less effective than the alternative ('dominated'). Interventions falling in this quadrant are never considered cost-effective regardless of  $\lambda$ . The NE quadrant, with positive costs and positive effects, and the SW quadrant, with negative costs and negative effects, involve trade-offs. These two quadrants represent the situation where the intervention may be cost-effective compared with the alternative, depending upon whether the ICER is above or below the given value of  $\lambda$ .

As illustrated in Fig. 1, the scatter plot commonly covers all four quadrants, indicating uncertainty about whether or not the intervention is cost-effective, and at what value it is cost-effective. The purpose of the CEAC is to summarise this uncertainty.

The CEAC is constructed by plotting the proportion of the costs and effects pairs that are cost-effective for a range of values of  $\lambda$ . This proportion is easily identifiable from the incremental cost-effectiveness plane as the proportion of points falling to the south and east of a ray through the origin with slope equal to  $\lambda$ . The process of constructing a CEAC begins by calculating this proportion with a ray of slope zero (equivalent to the  $x$ -axis). The process is repeated numerous times for rays of larger and larger slopes, up to a maximum value for  $\lambda$  of infinity (equivalent to the  $y$ -axis).

ELISABETH FENWICK, PhD, Department of Economics and Related Studies, University of York;  
SARAH BYFORD, MSc, Centre for the Economics of Mental Health, Institute of Psychiatry, De Crespigny Park,  
London, UK

Correspondence: Dr Elisabeth Fenwick, Department of Economics and Related Studies, University of York, Heslington, York YO10 5DD, UK. Tel: +44(0) 1904 321451; fax: +44(0) 1904 321402; e-mail: ealf100@york.ac.uk

(First received 28 April 2004, final revision 14 September 2004, accepted 4 November 2004)

Points in the NW quadrant are never considered cost-effective and therefore never counted. Points in the SE are always considered cost-effective and therefore always counted. As the slope of the ray is increased from zero to infinity, points in the NE and SW quadrants may or may not be considered cost-effective depending upon the value of  $\lambda$ . For more details concerning the shape of the CEAC see Fenwick *et al* (2004).

To illustrate this using the example from Haddock *et al* (2003), 693 out of 1000 bootstrap re-samples involved cost savings (fell below the  $x$ -axis), hence 69.3% of the costs and effects pairs fell to the south and east of a ray with slope zero, and as a result the CEAC crosses the  $y$ -axis at 69.3%. For a ray with a slope of £20 per point increase in GAF score, the proportion of the re-samples that were cost-effective was 70%, and for a ray with a slope of £655 per point increase in GAF score the proportion was 90%. In this way, a CEAC is generated.

## HOW IS A CEAC INTERPRETED?

The CEAC indicates the probability that the intervention is cost-effective compared with the alternative, given the data and for a given value of the maximum acceptable ratio ( $\lambda$ ). In the example of Haddock *et al* (2003), given a maximum acceptable ratio of £20 per point increase in GAF score, the probability that cognitive-behavioural therapy is cost-effective compared with routine treatment is 0.7. This is equivalent to stating that, given the data, there is a 70% chance that the additional cost of cognitive-behavioural therapy, compared with routine treatment, is less than £20 per point increase in GAF score. Note the comparative nature of both statements. It is *not* equivalent to stating that

cognitive-behavioural therapy has a 70% chance of costing less than £20 per point increase in GAF score.

Care must be taken when interpreting the information provided by a CEAC. A CEAC simply presents the *probability* that an intervention is cost-effective compared with the alternative for a range of values of  $\lambda$ . That is, the *probability* that the ICER falls below the maximum acceptable ratio. Statements concerning CEACs should be restricted to the uncertainty of the estimate of cost-effectiveness. The information from a CEAC *should not*, in general, be used to make statements about the implementation of the intervention.

## REFERENCES

- Bower, P., Byford, S., Barber, J., et al (2003)** Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses. *British Medical Journal*, **326**, 1247–1250.
- Briggs, A. & Fenn, P. (1998)** Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. *Health Economics*, **7**, 723–740.
- Briggs, A. & Gray, A. (1999)** Handling uncertainty when performing economic evaluation of healthcare interventions. *Health Technology Assessment*, **3**, 2.
- Byford, S., Knapp, M., Greenshields, J., et al (2003)** Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a rational decision making approach. *Psychological Medicine*, **33**, 977–986.
- Fenwick, E., Claxton, K. & Sculpher, M. (2001)** Representing uncertainty: the role of cost-effectiveness acceptability curves. *Health Economics*, **10**, 779–787.
- Fenwick, E., O'Brien, B. & Briggs, A. (2004)** Cost-effectiveness acceptability curves – facts, fallacies and frequently asked questions. *Health Economics*, **13**, 405–415.
- Haddock, G., Barrowclough, C., Tarrier, N., et al (2003)** Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18-month outcomes of a randomised controlled trial. *British Journal of Psychiatry*, **183**, 418–426.
- Lothgren, M. & Zethraeus, N. (2000)** Definition, interpretation and calculation of cost-effectiveness acceptability curves. *Health Economics*, **9**, 623–630.

**McCrone, P., Knapp, M., Proudfoot, J., et al (2004)**

Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial. *British Journal of Psychiatry*, **185**, 55–62.

**Miller, P., Chilvers, C., Dewey, M., et al (2003)**

Counselling versus antidepressant therapy for the

treatment of mild to moderate depression in primary care: economic analysis. *International Journal of Technology Assessment in Health Care*, **19**, 80–90.

**O'Brien, B. & Briggs, A. (2002)** Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. *Statistical Methods in Medical Research*, **11**, 455–468.

**Scott, J., Palmer, S., Paykel, E., et al (2003)** Use of cognitive therapy for relapse prevention in chronic depression: cost-effectiveness study. *British Journal of Psychiatry*, **182**, 221–227.

**Van Hout, B. A., Al, M. J., Gordon, G. S., et al (1994)** Costs, effects and C/E-ratios alongside a clinical trial. *Health Economics*, **3**, 309–319.